All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Reported results | 2004-000775-34 | A double-blind, randomised, parallel group study to evaluate the safety, tolerability and efficacy of TAK-475 alone or co-administered with atorvastatin in patients with primary dyslipidemia | 2007-05-15 | due-trials |
Other | 2004-001720-21 | A Phase III, multi-center, randomized, double-blind comparator study to evaluate the efficacy and safety of 50 mg and 100 mg of TAK-013 tablets administered twice daily versus 3.75mg of Leuprolide adm... | not-yet-due | |
Other | 2004-001721-13 | A Phase III, multi-center, randomized, double-blind study to evaluate the efficacy and safety of 50 mg and 100 mg of sufugolix (TAK-013) tablets administered twice daily versus placebo for 12 weeks in... | not-yet-due | |
Reported results | 2004-002157-30 | A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Oral TAK-715 in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis | 2006-09-13 | due-trials |
Completed, but no date, and reported results | 2004-002231-92 | A Phase II Study of AP23573, an mTOR Inhibitor, in Patients with Advanced Sarcoma | bad-data | |
Reported results | 2004-002567-24 | A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis | 2007-04-04 | due-trials |
Reported results | 2004-003829-28 | An open-label investigation into the tolerability and pharmacokinetic / pharmacodynamic effects of sufugolix (TAK-013), at a dosage of 100mg twice-daily, during six months treatment of pre-menopausal ... | 2005-08-31 | due-trials |
Reported results | 2004-003962-14 | Candesartan "added" Treatment for Optimisation of Heart Failure (HF) Therapy - Effects on BNP and other HF associated Parameters. An open, non-controlled and multicentre trial | 2006-08-24 | due-trials |
Reported results Terminated | 2004-004226-28 | Effects of Pioglitazone in Patients with Type 2 Diabetes Mellitus and Coronary Heart Disease at High Risk for Cardiovascular Complications | 2006-11-21 | due-trials |
Reported results | 2004-004350-91 | A multicentre, randomised, double-blind, double-dummy, placebo-controlled study to evaluate the safety and efficacy of ramelteon compared to placebo with zopiclone as a reference arm in adults with ch... | 2006-10-02 | due-trials |
Reported results | 2004-004351-20 | A randomised, double-blind, placebo-controlled study to determine the long-term efficacy and safety of ramelteon in adults with chronic insomnia. | 2006-12-15 | due-trials |
Reported results | 2004-004463-30 | Effects of Pioglitazone in Combination with Atorvastatin in Comparison to Atorvastatin treatment alone on Intima-Media Thickness in patients at Risk for Vascular Complications | 2006-10-23 | due-trials |
Reported results | 2004-005094-29 | A Phase II Study of AP23573, a mTOR Inhibitor, in Female Adult Patients with Recurrent or Persistent Endometrial Cancer | 2010-01-15 | due-trials |
Reported results | 2005-000730-20 | An open label, international, multi centre, parallel group, phase III b, randomised trial, investigating lumbar spine Bone Mineral Density (BMD) changes in postmenopausal women with primary osteoporos... | 2011-01-14 | due-trials |
Reported results Terminated | 2005-001306-87 | EFFECTS OF CANDESARTAN CILEXETIL VS STANDARD THERAPY ON SERUM LEVELS OF BRAIN NATRIURETIC PEPTIDE IN PATIENTS SUFFERING FROM CHRONIC HEART FAILURE WITH DEPRESSED AND PRESERVED SYSTOLIC FUNCTION | 2008-05-27 | due-trials |
Reported results | 2005-002313-21 | A placebo-controlled, double-blind, randomized study to evaluate the efficacy and safety of TAK-475 50mg and 100mg versus placebo, when co-administered with simvastatin 20mg or 40mg in subjects with p... | 2007-03-02 | due-trials |
Reported results | 2005-002315-25 | A double-blind, double dummy, randomized, parallel group, multi-centre Phase III study to evaluate the efficacy and safety of TAK-475 100 mg and TAK-475 100 mg administered in combination with ezetimi... | 2008-01-09 | due-trials |
Reported results | 2005-002316-24 | A placebo-controlled, double-blind, randomised study to evaluate the efficacy and safety of TAK-475 100mg in subjects with type 2 diabetes currently treated with lipid-lowering therapy. | 2007-05-09 | due-trials |
Reported results | 2005-003561-16 | A Pivotal, Multicentre, Multinational, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-242 in Adults with Severe Sepsis | 2021-03-01 | due-trials |
Completed, but no date, and reported results Terminated | 2005-003626-26 | A double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475 or placebo when co-administered with current lipid-lowering therapy in subjects with homozygous fami... | bad-data | |
Reported results | 2005-003819-71 | A double-blind, placebo-controlled study followed by a repeat dosing phase to assess the efficacy and safety of DX-88 recombinant plasma kallikrein inhibitor for the treatment of acute attacks of ... | 2007-09-21 | due-trials |
Reported results | 2005-004667-36 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination with a Sulfonylurea in Subjects with Type 2 Diabe... | 2007-06-20 | due-trials |
Reported results | 2005-004668-22 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination with Metformin in Subjects with Type 2 Diabetes | 2007-07-30 | due-trials |
Reported results | 2005-004669-40 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination with Pioglitazone in Subjects with Type 2 Diabete... | 2007-08-02 | due-trials |
Reported results | 2005-004670-24 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) Compared with Placebo in Subjects with Type 2 Diabetes | 2007-07-05 | due-trials |
Reported results | 2005-004671-38 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination with Insulin in Subjects with Type 2 Diabetes | 2007-05-17 | due-trials |
Reported results | 2005-004672-20 | A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR110322 (SYR-322) in Subjects with Type 2 Diabetes | 2011-11-15 | due-trials |
Reported results | 2005-004876-19 | A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 100 mg or Placebo When Co-Administered With High Dose Statin Therapy in Subjects With Primary Hypercholesterolemia | 2008-03-28 | due-trials |
Reported results | 2005-004944-30 | An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection (Hematide™) in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney... | 2016-10-24 | due-trials |
Reported results | 2005-005641-19 | 3 Months, Open-Label, Parallel-Group Study of the Pharmacodynamics, Pharmacokinetics and Safety of TAP-144SR 1-month Depot Gelatin-Free vs. Gelatin-Containing Formulation in Female Patients with Uteri... | 2008-12-19 | due-trials |
Reported results | 2005-005863-26 | A Phase 2, double blind, placebo controlled, dose-ranging study in subjects with post herpetic neuralgia (PHN) to evaluate the efficacy, safety, tolerability and pharmacokinetics of four doses of TAK-... | 2008-02-05 | due-trials |
Reported results | 2005-006165-14 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study of the Efficacy, Safety, and Pharmacokinetics of MLN3897 in Patients with Rheumatoid Arthritis Taking Methotrexate | 2007-09-12 | due-trials |
Reported results | 2006-000694-30 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS) in Subjects with Type 2 D... | 2008-03-17 | due-trials |
Completed, but no date, and reported results | 2006-000725-54 | Double-blind, randomized, multicenter, parallel-group study to evaluate the effects of pioglitazone on metabolic syndrome in patients with type 2 diabetes treated with metformin | bad-data | |
Reported results | 2006-001998-25 | Double-blind, randomised trial to investigate the antihypertensive and metabolic effects of candesartan in insulin-resistant obese patients with a hypertension not adequately controlled by previous be... | 2008-09-24 | due-trials |
Reported results | 2006-002237-20 | Pilot trial studying the Effects of Pioglitazone in Comparison to Placebo on Myocardial Function and Oxidative Stress in Patients with Type II Diabetes and Insulin Resistance undergoing elective PTCA | 2010-01-25 | due-trials |
Reported results | 2006-002271-41 | Effects of Pioglitazone in Combination with Glimepiride in Comparison to Glimepiride Monotherapy on Metabolic Control in Patients with Type 2 Diabetes mellitus | 2008-12-16 | due-trials |
Reported results | 2006-002354-30 | Effect of Acute Insulin Intervention followed by Pioglitazone and Metformin Treatment on Metabolic Parameters in Type 2 Diabetic Patients with inadequate Metabolic Control | 2007-01-23 | due-trials |
Reported results | 2006-003054-26 | A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate the Safety and Efficacy of Oral TAK-783 in the Treatment of the Signs and Symptoms of in Subjects with Rheumatoid Arth... | 2009-02-24 | due-trials |
Reported results | 2006-004028-35 | Effect of Pioglitazone compared to a combination therapy with Ramipril and to a Ramipril monotherapy on low grade inflammation and vascular function in patients with increased cardiovascular risk and ... | 2008-05-21 | due-trials |
Reported results | 2006-004455-37 | Effects of a Pioglitazone/ Metformin Fixed Combination in Comparison to Metformin in Combination with Glimepiride on Diabetic Dyslipidemia | 2009-05-13 | due-trials |
Reported results | 2006-005492-17 | A Multicenter, Double-Blind Study to Determine the Efficacy and Safety of SYR-322 plus Pioglitazone HCl (Actos), SYR-322 Alone or Pioglitazone HCl Alone in Subjects with Type 2 Diabetes | 2008-02-13 | due-trials |
Reported results | 2006-006025-73 | A Multicenter, Randomized, Double-Blind Study to Determine the Efficacy and Safety of the Addition of SYR-322 25 mg versus Dose Titration from 30 mg to 45 mg of ACTOS Pioglitazone HCl in Subjects wit... | 2009-06-05 | due-trials |
Reported results | 2007-000240-27 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Weekly Treatment with SYR-472 in Subjects with Type 2 Diabetes. | 2008-03-13 | due-trials |
Reported results | 2007-000403-15 | A Randomized, Double-Blind, Placebo-Controlled, Polysomnography plus Outpatient Study to Determine the Safety and Efficacy of 4 mg Ramelteon in Adults with Chronic Insomnia | 2008-03-28 | due-trials |
Reported results | 2007-000486-38 | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing SYR-322 Alone and Combination SYR-322 with Pioglitazone versus Placebo on Postprandial Lipids in Subjects w... | 2009-12-17 | due-trials |
Reported results | 2007-001489-34 | A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg versus Placebo in Subjects with Hypercholesterolemia, With an Optional Open-Label Extension | 2008-05-07 | due-trials |
Reported results | 2007-002583-10 | A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Ramipril in Subjects With Essential Hypertension | 2009-04-21 | due-trials |
Reported results | 2007-002875-15 | A Single-Center, Randomized, Double-Blind, Double-Dummy Placebo Controlled, Cross-Over Study to Investigate the Next Morning Effects of Ramelteon (8mg), Zopiclone (7.5mg) and Placebo on Actual Driving... | 2008-05-05 | due-trials |
Reported results Terminated | 2007-003070-26 | Candesartan “added” therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, pa... | 2008-10-31 | due-trials |
Completed, but no date, and reported results | 2007-003077-44 | EffectS of PiogLitazone on ENDOthelial progenitoR cells in type 2 diabetic patients with vascular complications - The SPLENDOR Study | bad-data | |
Reported results | 2007-003462-18 | A Pivotal Trial to Determine the Efficacy and Safety of AP23573 (Ridaforolimus) when Administered as Maintenance Therapy to Patients with Metastatic Soft-Tissue or Bone Sarcomas | 2014-09-18 | due-trials |
Reported results | 2007-005687-27 | A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of TAK-242 Versus Placebo in Subjects With Sepsis Induced Cardiovascular and Respiratory Failure | 2009-02-28 | due-trials |
Reported results | 2007-006706-14 | Impact of Pioglitazone, Metformin and the combination of both on cardiovascular risk in insulin-treated patients with Type 2 diabetes – The PIOcomb Study | 2010-07-28 | due-trials |
Reported results | 2007-006744-21 | Comparison of the Effects of Pioglitazone vs. Placebo when given in addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus and Renal Failure – The PIOren Study | 2010-06-29 | due-trials |
Reported results | 2008-000091-24 | A Phase 2, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes | 2010-06-21 | due-trials |
Reported results | 2008-000634-53 | A randomized phase II trial of deforolimus (AP23573; MK-8669) compared to progestin in female adult patients with advanced endometrial carcinoma following one line of chemotherapy | 2012-07-09 | due-trials |
Reported results | 2008-000959-10 | A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Subjects with Type 2 Diabetes | 2010-08-30 | due-trials |
Reported results | 2008-001580-11 | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder | 2009-08-13 | due-trials |
Reported results | 2008-001581-91 | A Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 in Subjects With Major Depressive Disorder | 2010-08-23 | due-trials |
Reported results | 2008-001766-90 | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of a Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety ... | 2009-07-07 | due-trials |
Reported results | 2008-001971-30 | A Phase II Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination with Trastuzumab for Patients with HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer | 2011-05-10 | due-trials |
Reported results | 2008-002782-32 | A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe ... | 2013-12-09 | due-trials |
Reported results | 2008-002783-33 | A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe C... | 2014-02-19 | due-trials |
Reported results | 2008-002784-14 | A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohn?s Disease Estudio abierto, de fase 3 para determinar la eficacia y ... | 2017-10-31 | due-trials |
Reported results | 2008-003458-13 | A Phase 2 Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Subjects Previously Treated With Epoetin | 2010-05-19 | due-trials |
Reported results | 2008-003459-64 | A Phase 2 Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Subjects with Chronic Renal Failure Who Are on Hemodialysis or Do Not Require Dialysis and ... | 2009-12-24 | due-trials |
Reported results | 2008-004218-28 | A Phase 3, Double-Blind, Randomized, Factorial, Efficacy and Safety Study of TAK 491 Plus Chlorthalidone Fixed-Dose Combination in Subjects with Moderate to Severe Hypertension | 2010-07-10 | due-trials |
Reported results | 2008-006906-41 | A Modified Case Control Study To Identify Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure To Lapaquistat Acetate | 2010-05-22 | due-trials |
Reported results | 2008-006977-34 | A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients with Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome | 2011-07-04 | due-trials |
Reported results | 2008-006979-72 | A Phase 2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of Patients with Platinum-Refractory or Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Car... | 2011-01-27 | due-trials |
Reported results | 2008-006981-27 | A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gast... | 2014-04-25 | due-trials |
Reported results | 2008-007444-34 | A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide When Used in Combination with Metformin in Su... | 2012-10-17 | due-trials |
Reported results | 2008-008260-28 | A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-Dose... | 2011-11-17 | due-trials |
Trial is outside EEC, and reported results | 2009-011221-13 | A Comparative, Randomized, Open-Label, Multi-Center, Single Dose Pharmacokinetic, Pharmacodynamic and Safety Study of Alogliptin (12.5 mg and 25 mg) Between Children, Adolescents, and Adults with Type... | bad-data | |
Reported results | 2009-011222-34 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabet... | 2013-06-18 | due-trials |
Reported results | 2009-011428-79 | Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritonea... | 2017-07-19 | due-trials |
Reported results | 2009-011776-30 | Clinical Study to Evaluate the Efficacy and Safety of the Combination Therapy Candesartan Cilexetil 32 mg plus Hydrochlorothiazide 25 mg in Patients with Severe Hypertension | 2010-06-17 | due-trials |
Reported results | 2009-012652-24 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin Plus Metformin, Alogliptin Alone, or Metformin Alone in Subjects with Type 2 Diabet... | 2011-06-30 | due-trials |
Reported results | 2009-013056-71 | Ensayo abierto, aleatorizado, multicentrico, controlado con grupo paralelo para evaluar la eficacia y seguridad de TachoSilâ frente a la práctica habitual en técnicas de sellado de duramadre para la... | 2013-09-06 | due-trials |
Trial is partly outside EEC, and reported results | 2009-013165-25 | A Comparative Single-Dose Pharmacokinetic and Safety Study of TAK-491 Between Infants, Children, and Adolescents with Hypertension and Healthy Adults | 2013-09-09 | bad-data |
Reported results | 2009-016488-12 | A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn’s Disease | 2014-01-30 | due-trials |
Exempt, with results | 2009-017668-18 | A Phase 1/2, Open-Label Study in Men with Prostate Cancer to Assess the Safety, Pharmacokinetics, and Testosterone-Lowering Efficacy of TAK-448, Administered as a 1 Month Depot, Including a Randomized... | 2011-09-09 | not-yet-due |
Reported results | 2010-018661-35 | A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Pr... | 2016-04-07 | due-trials |
Reported results | 2010-018662-23 | A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK 700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That ... | 2016-02-29 | due-trials |
Reported results | 2010-019685-87 | Effect of roflumilast on exacerbation rate in patients with COPD treated with fixed combinations of LABA and ICS. A 52-week, randomised double-blind trial with roflumilast 500 ?g versus placebo Efe... | 2014-07-31 | due-trials |
Reported results | 2010-020414-28 | A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients with Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia | 2019-01-17 | due-trials |
Reported results | 2010-022257-41 | A Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of Lu AA21004 in Patients with Major Depressive Disorder | 2012-04-25 | due-trials |
Reported results Terminated | 2010-022716-39 | A 3-Part Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Subcutaneous Ecallantide in Prepubertal Paediatric Patients Experiencing Acute Attacks of Hereditary Angioedema | 2015-04-01 | due-trials |
Reported results | 2010-023098-21 | A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and Hydrochlorothiazide Fixed-... | 2012-10-11 | due-trials |
Reported results | 2010-023772-71 | An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of MLN9708, a Next-Generation Proteasome Inhibitor, Administered in Combination with a Standard Care Regimen of Melphalan and Prednis... | 2016-12-30 | due-trials |
Reported results | 2010-024215-14 | A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Sperimentazio... | 2018-07-06 | due-trials |
Reported results | 2011-000220-16 | A Phase-3 Randomized, Double-Blind, Efficacy and Safety Study Evaluating the Fixed Dose Combinations of TAK-491 Plus Chlorthalidone (40/12.5 mg and 40/25 mg) in Subjects With Grades 2 or 3 Essential H... | 2013-01-24 | due-trials |
Reported results | 2011-000582-13 | A 16-week, randomized, placebo-controlled, double blind, and parallel group trial to assess the anti-inflammatory effects of Roflumilast in chronic obstructive pulmonary disease The ROBERT study (Rofl... | 2016-02-11 | due-trials |
Ongoing | 2011-000609-32 | A Multicenter, Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab and Vincristine | not-yet-due | |
Reported results | 2011-000683-99 | Control of moderate or severe asthma with 160, 320 and 640μg ciclesonide/day. A one-year randomised, double-blind, multicenter trial. | 2014-11-17 | due-trials |
Reported results | 2011-001240-29 | A Phase 1/2 Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma | 2018-04-12 | due-trials |
Reported results | 2011-001731-24 | A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Glimepiride When Used in Combination with Metformin... | 2014-04-24 | due-trials |
Reported results | 2011-001732-37 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects with Type 2 Diabetes and wi... | 2014-05-05 | due-trials |
Reported results Terminated | 2011-001752-10 | A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Placebo and Sitagliptin 100 mg When Us... | 2013-12-27 | due-trials |
Reported results | 2011-002741-35 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared with Placebo in Subjects with Type 2 Diabetes | 2013-07-05 | due-trials |
Reported results | 2011-003545-18 | A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Periphera... | 2018-04-16 | due-trials |
Reported results | 2011-005298-22 | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects with Major Depressive Di... | 2014-02-05 | due-trials |
Other | 2011-005450-60 | A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma Studio di Fase 3, randomizzato, in aperto su A+AVD rispetto ad... | not-yet-due | |
Listed as ongoing, but also has a completion date and reported results | 2011-005468-10 | A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refracto... | 2022-07-11 | bad-data |
Listed as ongoing, but also has a completion date and reported results | 2011-005496-17 | A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed a... | 2022-02-08 | bad-data |
Exempt, with results | 2011-005718-12 | A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113 Estudio en fase 1/2 sobre la seguridad, tolerabilidad, far... | 2020-02-18 | not-yet-due |
Reported results | 2012-000136-26 | A Phase 2, Open-Label, Single-Arm, Multidose Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer | 2015-01-21 | due-trials |
Reported results | 2012-001355-38 | A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Studio di Fase III, Randomizzato, in Aperto, c... | 2013-10-18 | due-trials |
Reported results Terminated | 2012-001357-10 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1 mg and ... | 2014-07-30 | due-trials |
Exempt, with results | 2012-001539-30 | A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients with Castration-Resistant Prostate Cancer | 2016-09-01 | not-yet-due |
Reported results | 2012-001680-72 | A Phase 2 Open-Label, Multicenter, 4-Week Study to Assess the safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed- Release Capsules for Relief of Heartburn, in Adolescent ... | 2014-01-21 | due-trials |
Reported results | 2012-001681-15 | A Phase 2 Multicenter, 36-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed- Release Capsules for Healing of Erosive Esophagitis and Maintenance... | 2014-11-10 | due-trials |
Reported results | 2012-002064-27 | A Phase 2, Randomized, Double-blind, 4-week Cross-over Trial to Investigate The Effect of a Once-daily Combination of 500 µg Roflumilast plus 10 mg Montelukast versus 10 mg Montelukast Alone on Pulmon... | 2013-10-24 | due-trials |
Exempt, with results | 2012-002998-62 | A Randomized, Single-Center, Observer-Blind, Vehicle- and Active Comparator-Controlled Phase 1b Study to Assess the Effect and Local Safety and Tolerability Of Roflumilast and BYK321084 – Phosphodiest... | 2013-10-30 | not-yet-due |
Reported results | 2012-003000-12 | A Phase 2a, 15-Day, Randomized, Parallel Group, Double-Blind, Multi-Centre, Vehicle Controlled Trial to Assess the Efficacy and Local Safety of a Cream Containing 0.5% Roflumilast - a Phosphodiesteras... | 2014-03-18 | due-trials |
Reported results | 2012-003111-58 | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer’s Di... | 2018-08-07 | due-trials |
Exempt | 2012-003775-20 | An Open-label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients with Metachromatic Leukodystrophy | not-yet-due | |
Ongoing | 2012-004128-39 | A Phase 4, Open?label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Estudio de fase 4, abierto, con un único grupo de trat... | not-yet-due | |
Ongoing | 2012-005653-22 | TachoSil patch application as replacement of closed suction wound drainage by parotid gland surgery; a prospective study. TachoSil applicatie als vervanging van wonddrainage bij parotischirurgie; e... | not-yet-due | |
Reported results | 2012-005732-28 | A multicentre, open-label switch study to investigate the necessity of dose adjustment after switching from L-Thyroxine Christiaens® to the new levothyroxine sodium test formulation in (near) total th... | 2014-06-23 | due-trials |
Reported results Terminated | 2013-000007-17 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50mg Compared With Placebo as an Add-On to Glimepiride in ... | 2013-12-27 | due-trials |
Reported results | 2013-000232-10 | A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy | 2020-03-12 | due-trials |
Reported results | 2013-000326-54 | A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagno... | 2022-06-24 | due-trials |
Reported results Terminated | 2013-000542-19 | A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Sitagliptin 100 mg When Used in Combina... | 2013-12-27 | due-trials |
Reported results Terminated | 2013-000886-35 | A Phase 2 Randomized, Placebo-Controlled, Double-Blind Parallel-Group, Multicenter Study to Evaluate the Glycemic Effects and Safety of Fasiglifam 25 mg Twice Daily and 50 mg Once Daily on Glycemic Co... | 2013-12-27 | due-trials |
Reported results | 2013-001419-64 | A Phase II, Randomized, Controlled, Double-Blind, Dosage and Adjuvant Justification, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Adjuvant... | 2015-06-15 | due-trials |
Reported results | 2013-001788-21 | A multicenter, randomized, double-blind phase 3 study to evaluate tolerability and pharmacokinetics of 500μg roflumilast once daily with an up-titration regimen in COPD, including an open-label down-t... | 2015-11-30 | due-trials |
Listed as ongoing, but also has a completion date | 2013-002076-41 | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant | 2023-09-08 | bad-data |
Reported results | 2013-002134-21 | A Randomized Phase 2 Study of AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated with Crizotinib | 2020-02-27 | due-trials |
Reported results | 2013-002302-32 | An Open-label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma | 2017-03-23 | due-trials |
Reported results | 2013-002805-76 | A 24-week randomized, double-blind, placebo-controlled, phase 2 dose finding study to evaluate the efficacy and safety of 3 doses of namilumab (20 mg, 80 mg and 150 mg) in combination with methotrexat... | 2016-11-16 | due-trials |
Reported results | 2013-002806-30 | A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding and Proof of Concept Study, to Assess the Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Namilum... | 2016-02-23 | due-trials |
Reported results | 2013-003113-17 | An Open-Label, Phase 2 Study to Evaluate the Oral Combination of MLN9708 With Cyclophosphamide and Dexamethasone In Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiri... | 2018-06-29 | due-trials |
Reported results | 2013-003713-18 | A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Sm... | 2017-07-10 | due-trials |
Reported results | 2013-004984-30 | A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Compl... | 2018-05-08 | due-trials |
Trial is partly outside EEC, and reported results | 2014-000778-20 | A Phase II, Randomized, Double-Blind, Dosage, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine combined with Aluminum Hydroxide adjuvant in Ch... | 2018-06-20 | bad-data |
Reported results Terminated | 2014-000804-88 | A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC) | 2016-01-15 | due-trials |
Reported results | 2014-000805-11 | A Phase 2 Trial of MLN0264 in Previously Treated Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC) | 2016-01-15 | due-trials |
Listed as ongoing, but also has a completion date and reported results | 2014-001394-13 | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Tr... | 2022-08-26 | bad-data |
Listed as ongoing, but also has a completion date | 2014-001617-12 | A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses | 2018-01-16 | bad-data |
Exempt, with results | 2014-001642-16 | A Phase 1, Randomized, Open-Label, Parallel-Design, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Capsules in Infants Aged 1 to 11... | 2020-02-10 | not-yet-due |
Reported results | 2014-001921-34 | A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast... | 2018-07-03 | due-trials |
Reported results Terminated | 2014-002155-25 | An Open-Label, Phase 2a Study to Evaluate the Pharmacodynamics of Different Dosing Regimens of TAK-448, a Kisspeptin Agonist, in Male Overweight/Obese Subjects With Hypogonadotropic Hypogonadism | 2015-12-04 | due-trials |
Reported results | 2014-002945-23 | A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs Adal... | 2016-11-01 | due-trials |
Reported results | 2014-003509-13 | An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab IV | 2018-02-21 | due-trials |
Reported results | 2014-003942-28 | Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying In... | 2017-02-23 | due-trials |
Listed as ongoing, but also has a completion date | 2014-004281-25 | A Phase 1b/Adaptive Phase 2 Study of Docetaxel With or Without MLN1117 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | 2016-09-15 | bad-data |
Ongoing | 2014-004506-15 | A Phase 2, Double-Blind, 12 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 1 to 11 Y... | not-yet-due | |
Ongoing | 2014-004507-73 | A Phase 2, Double Blind, Up to 40 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophag... | not-yet-due | |
Reported results Terminated | 2014-005142-21 | A Multicenter, Randomized, Double Blind, Placebo Controlled, Proof of Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Weekly Subcutaneous MLN1202, in Improving Diabetic Nephropathy Subje... | 2015-11-17 | due-trials |
Reported results | 2014-005394-37 | A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3K? Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, R... | 2020-10-30 | due-trials |
Reported results | 2014-005619-18 | A Randomized, Open-Label, 2-Way Cross-over, Phase 4 Study to Evaluate Subject Preference and Acceptability of a New Formulation of Calcichew D3 in Adult Patients Eligible for Calcium and Vitamin D Sup... | 2015-08-21 | due-trials |
Trial is partly outside EEC, and reported results | 2015-000208-25 | A Multicenter, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 Diabetes Mellitus | 2022-02-14 | bad-data |
Reported results | 2015-000221-37 | A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients with Higher-Risk Myelodysplastic S... | 2021-07-23 | due-trials |
Reported results | 2015-000480-14 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study, with a Vedolizumab IV Reference Arm, to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects Wi... | 2018-10-08 | due-trials |
Reported results | 2015-000481-58 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn... | 2019-10-14 | due-trials |
Listed as ongoing, but also has a completion date | 2015-000482-31 | A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects with Ulcerative Colitis and Crohn?s Disease Estudio abierto, de fase IIIb para est... | 2022-07-13 | bad-data |
Reported results | 2015-000852-12 | A Randomized Double-Blind Phase 4 Study to Evaluate the Safety and Proportion of Subjects With Fistula Healing in 2 Dose Regimens of Entyvio (Vedolizumab IV) in the Treatment of Fistulizing Crohn's Di... | 2018-11-14 | due-trials |
Reported results | 2015-000939-33 | A Randomized, Double-Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects With Ulcerative Colitis | 2019-03-11 | due-trials |
Reported results | 2015-001154-14 | A Randomized, Double-Blind, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Once Daily Oral Vonoprazan 20 mg or Vonoprazan 40 mg Compared to Esomeprazole 40 mg for the Treatment... | 2018-10-12 | due-trials |
Listed as ongoing, but also has a completion date and reported results | 2015-001318-92 | A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib | 2021-01-20 | bad-data |
Reported results | 2015-002133-22 | A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced... | 2020-10-13 | due-trials |
Trial is partly outside EEC | 2015-002136-40 | A study of safety, effect on the immune system and blood clotting of BAX855 (factor VIII of blood clotting) in pediatric patients who have not received or received minimal treatment for their severe h... | bad-data | |
Listed as ongoing, but also has a completion date and reported results | 2015-003447-19 | A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer | 2021-01-29 | bad-data |
Listed as ongoing, but also has a completion date and reported results | 2015-003472-78 | A Randomized, Double-Blind, Placebo-Controlled Phase 4 Study to Evaluate the Efficacy and Safety of Entyvio (Vedolizumab IV) in the Treatment of Chronic Pouchitis | 2021-02-09 | bad-data |
Reported results Terminated | 2015-003612-20 | An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or ... | 2019-11-25 | due-trials |
Reported results | 2015-003943-20 | HELP Study™: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate DX 2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE) | 2017-04-13 | due-trials |
Listed as ongoing, but also has a completion date and reported results | 2015-004112-38 | An Open-Label Study of Brentuximab Vedotin+Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma Estudio abierto con Brentuximab Vedoti... | 2021-09-24 | bad-data |
Trial is partly outside EEC, and reported results | 2015-004726-34 | A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegalovirus (... | 2022-07-01 | bad-data |
Reported results | 2015-005255-27 | HELP Study ExtensionTM: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) | 2019-10-31 | due-trials |
Reported results | 2016-000678-40 | Entyvio (Vedolizumab IV) Extended Access Program in Ulcerative Colitis and Crohn¿s Disease Programma di accesso allargato a Entyvio (Vedolizumab EV) nella colite ulcerosa e nel morbo di Crohn | 2023-03-01 | due-trials |
Ongoing | 2016-001271-68 | A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer | not-yet-due | |
Trial is partly outside EEC | 2016-001477-33 | A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding... | bad-data | |
Ongoing | 2016-001681-28 | An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies. | not-yet-due | |
Reported results | 2016-002985-30 | An Open-Label, Dose-Finding Study of Vedolizumab IV for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Patients who Have Undergone Allogeneic Hematopoietic Stem C... | 2018-06-04 | due-trials |
Reported results | 2016-003716-12 | Phase 2 Study of TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After at Least 2 Prior Lines of Chemotherapy | 2019-12-17 | due-trials |
Reported results | 2016-004288-37 | A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects who have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine | 2021-07-22 | due-trials |
Listed as ongoing, but also has a completion date and reported results | 2016-004742-28 | A Phase 2, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma | 2021-11-26 | bad-data |
Ongoing | 2017-000318-40 | A Phase 3, Randomized, Controlled, Open-Label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syn... | not-yet-due | |
Reported results | 2017-001071-23 | A Randomized, Observer Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Tetravalent Dengue Vaccine Candidate (TDV) and an Intramuscular Hepa... | 2019-07-09 | due-trials |
Reported results Terminated | 2017-001084-20 | A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Subjects With... | 2019-11-06 | due-trials |
Other | 2017-001739-38 | A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects, Safety, Tolerability, and pharmacokinetics of Multiple Oral Doses of TAK-831 in Adult Subj... | not-yet-due | |
Ongoing | 2017-002182-21 | A Phase 2b, Extension Study to Determine the Long-term Safety of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease. (Long-term Safety With Vedolizumab IV in Pediatric Sub... | not-yet-due | |
Reported results | 2017-002231-41 | A Phase 2, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Safety and Tolerability of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease (A... | 2020-05-26 | due-trials |
Reported results Terminated | 2017-002232-16 | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-653 in the Treatment of Subjects with Treatment-Resistant Depression | 2018-02-01 | due-trials |
Other | 2017-002491-10 | Postauthorization Safety Study of the Long-Term Safety and Efficacy of Repeat Administration of Darvadstrocel in Patients With Crohn’s Disease and Complex Perianal Fistula | not-yet-due | |
Reported results Terminated | 2017-003206-41 | A Phase 2b, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous TAK-954 in Critically Ill Patients With Enteral Feeding Intole... | 2018-11-02 | due-trials |
Reported results | 2017-003471-54 | A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose levels of TAK-831 in Adjunctive Treatment of... | 2021-01-12 | due-trials |
Reported results | 2017-003977-32 | A Phase 2, Open-Label Study of Ixazomib + Daratumumab + Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) | 2023-06-26 | due-trials |
Ongoing | 2018-000397-30 | A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia... | not-yet-due | |
Ongoing | 2018-000635-27 | Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib | not-yet-due | |
Ongoing | 2018-000821-29 | A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-label ... | not-yet-due | |
Reported results | 2018-001275-21 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a Peripherally Acting Dopamine Rec... | 2021-06-14 | due-trials |
Listed as ongoing, but also has a completion date | 2018-001957-29 | A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIGTM) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive on–Small-Cell Lung Cancer Patients Who Have Progressed o... | 2022-05-09 | bad-data |
Trial is partly outside EEC, and reported results | 2018-002141-11 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease in Subjects Underg... | 2022-05-09 | bad-data |
Reported results | 2018-002484-25 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-935 (OV935) AS AN ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS WITH DEV... | 2020-06-09 | due-trials |
Trial is partly outside EEC | 2018-002485-39 | A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEPSY ... | bad-data | |
Reported results | 2018-003318-42 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of 2 Dose Regimens of Intravenous TAK-954 for the Prophylaxis and Treatment of Postoperat... | 2022-06-06 | due-trials |
Reported results Terminated | 2018-003907-20 | Open-Label Phase 1 Study to Assess the Maximum Tolerated Dose, Pharmacokinetics, and Safety of Ixazomib Administered Intravenously to Pediatric Patients Aged 0 to <18 Years With Relapsed or Refractory... | 2020-09-18 | due-trials |
Trial is outside EEC, and reported results | 2018-003978-28 | A Phase II, Double-Blind, Controlled Trial to Assess the Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Subjects Aged Between 2 and ... | bad-data | |
Trial is outside EEC, and reported results | 2018-003979-34 | Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Childr... | bad-data | |
Trial is outside EEC, and reported results | 2018-003980-77 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of Subcutaneous Administration of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescen... | bad-data | |
Reported results | 2018-004750-21 | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Adult Subjects With Chronic Complex Regional Pa... | 2020-10-28 | due-trials |
Listed as ongoing, but also has a completion date | 2019-000333-39 | A Follow-up of a Phase 3 Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel in the Treatment of Complex Perianal Fistula in Subjects With Crohn’s Disease Who Have Participated in ADM... | 2024-04-02 | bad-data |
Listed as ongoing, but also has a completion date and reported results | 2019-000886-19 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn’s Dise... | 2022-08-26 | bad-data |
Trial is outside EEC, and reported results | 2019-001198-10 | A Phase 3, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Inductio... | bad-data | |
Trial is outside EEC, and reported results | 2019-001199-12 | Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Examine the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction... | bad-data | |
Listed as ongoing, but also has a completion date and reported results | 2019-001703-20 | A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema with ... | 2022-10-20 | bad-data |
Ongoing | 2019-001845-42 | A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Ex... | not-yet-due | |
Listed as ongoing, but also has a completion date | 2019-002549-39 | A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphobla... | 2024-07-19 | bad-data |
Ongoing | 2019-003117-33 | A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit ... | not-yet-due | |
Ongoing, reported early | 2019-003383-47 | A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis Studio di fase 2, randomizzato, controllato ... | not-yet-due | |
Listed as ongoing, but also has a completion date | 2019-004103-12 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Persistent/Chronic Primary Immune Thrombocytopenia Estudio de... | 2024-04-29 | bad-data |
Reported results | 2019-004823-20 | An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema with Normal C1-Inhibitor (C1-INH) | 2023-05-05 | due-trials |
Reported results | 2020-000777-24 | A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With... | 2021-11-05 | due-trials |
Other | 2020-003193-48 | A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects with Crohn’s Disease over a Period of 2... | not-yet-due | |
Ongoing | 2020-003304-13 | A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis with rVWF in Children Diagnosed With Severe von Willebrand disease | not-yet-due | |
Exempt, with results | 2020-003946-36 | Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma | 2023-04-26 | not-yet-due |
Exempt | 2020-003947-27 | An Open Label, Dose-Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetics of TAK-981 in Adult Patients With Advanced or Metastatic Solid Tumors o... | 2023-12-14 | not-yet-due |
Trial is partly outside EEC | 2020-004300-34 | A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Ulcerative Coli... | bad-data | |
Trial is partly outside EEC | 2020-004301-31 | A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Crohn's Disease... | bad-data | |
Ongoing | 2020-004325-23 | A Phase 1b/2 Study of TAK-981 Plus Pembrolizumab to Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced or Metastatic Solid Tumors | not-yet-due | |
Trial is partly outside EEC | 2020-005438-14 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-062 for the Treatment of Active Celiac Disease in Subjects Attempting a Gluten-Fr... | bad-data | |
Reported results | 2021-000251-39 | A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With ... | 2021-11-05 | due-trials |
Trial is partly outside EEC | 2021-000630-34 | A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Intravenous in Pediatric Patients With Ulcerative Colitis or Crohn’s Disease | bad-data | |
Trial is outside EEC | 2021-002051-10 | A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients with Status Epilepticus (Convulsive) in Community Settings | bad-data | |
Trial is partly outside EEC | 2021-002480-22 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult S... | 2024-04-11 | bad-data |
Trial is partly outside EEC, and reported results | 2021-002481-40 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subject... | 2024-01-25 | bad-data |
Trial is partly outside EEC | 2021-002482-17 | A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Len... | bad-data | |
Other | 2021-004138-12 | A Phase 3, Prospective, Randomized, Open-label, Adaptive Group Sequential, Multicenter Trial with Blinded Endpoint Assessment to Evaluate the Efficacy and Safety of PROTHROMPLEX TOTAL for the Reversal... | not-yet-due | |
Trial is partly outside EEC | 2021-004279-15 | A Phase 3, Open-label, Single-arm, Repeated-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infecti... | bad-data | |
Exempt | 2021-006038-37 | A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refract... | not-yet-due | |
Ongoing | 2022-000336-28 | A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple Sy... | not-yet-due | |
Exempt | 2022-000528-39 | An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult... | not-yet-due | |
Trial is outside EEC, and reported results | 2022-001315-44 | A Multicenter, Open-label, Pilot Study of TAK-935 (OV935) in Patients With 15Q Duplication Syndrome or CDKL5 Deficiency Disorder (ARCADE Study) | bad-data | |
Other | 2022-001418-20 | A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients With Multiple Myeloma Estudio en fase Ib abierto ... | not-yet-due | |
Listed as ongoing, but also has a completion date | 2022-001654-38 | A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1) | 2023-12-14 | bad-data |
Trial is outside EEC, and reported results | 2022-001873-29 | A Phase 3, Open-label, Non-controlled, Multi-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Efficacy of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Jap... | bad-data | |
Ongoing | 2022-001940-36 | A Phase 2b, multicenter, randomized, double-blind study of safety and efficacy of TAK-755 (rADAMTS13) with minimal to no plasma exchange (PEX) in the treatment of immune-mediated thrombotic thrombocyt... | not-yet-due | |
Completed, report not yet due Terminated | 2022-002169-14 | A Phase 1/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Modakafusp Alfa in Combination With Daratumumab Subcutaneous in Patients With Re... | 2024-05-22 | not-yet-due |
Trial is outside EEC | 2022-002323-35 | A Multicenter, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Velaglucerase Alfa in Chinese Subjects With Type 1 Gaucher Disease | bad-data | |
Trial is outside EEC, and reported results | 2022-002374-82 | A Phase 3, Open-Label, Single-Arm Study to Assess the Efficacy, Safety, and Pharmacokinetics of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Japanese Recipients of a Hematopoietic... | bad-data | |
Trial is outside EEC | 2022-002471-11 | An Open Label, Multicenter, Single-arm and Prospective Study to Assess the Efficacy and Safety of Leuprorelin 3M in the Treatment of Central Precocious Puberty (CPP) | bad-data | |
Trial is outside EEC, and reported results | 2022-002621-98 | A Phase 3 Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Lanadelumab (SHP643) in Japanese Subjects with Hereditary Angioedema | bad-data | |
Trial is outside EEC, and reported results | 2022-002627-35 | A Multicenter, Open-Label, Non-randomized Phase 3 Study to Assess the Safety, Efficacy and Pharmacokinetics of Subcutaneous Administration of Icatibant (TAK-667) in Japanese Children and Adolescents w... | bad-data | |
Other | 2022-002965-13 | A Long-term Extension Study to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia Conditions | not-yet-due | |
Listed as ongoing, but also has a completion date | 2022-002966-34 | A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2) | 2023-12-25 | bad-data |
Trial is outside EEC, and reported results | 2022-003221-22 | Phase 3, Multicenter, Randomized Study With 2 Different Doses of Prucalopride Administered to Male and Female Pediatric Subjects Aged 6 Months to 17 Years With Functional Constipation, Consisting of a... | bad-data | |
Trial is outside EEC, and reported results | 2022-003339-24 | A Phase 3, Open-Label, Randomized Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) and an Intramuscular... | bad-data | |
Trial is outside EEC | 2022-003400-32 | A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Participants with Primary Immunodeficiency Disease (PID) | bad-data | |
Trial is outside EEC, and reported results | 2022-003455-33 | A Double-Blind, Randomized, Placebo-Controlled, Age Descending and Expansion Phase 2 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers B... | bad-data | |
Trial is outside EEC, and reported results | 2022-003456-13 | An Open Label, Phase 2 Study to Investigate Cell-mediated Immunity and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Healthy Children Aged 4 to 16 Years | bad-data | |
Trial is outside EEC, and reported results | 2022-003572-16 | A Phase 3, Open-label Safety Study of Teduglutide in Japanese Pediatric Patients With Short Bowel Syndrome Who are Dependent on Parenteral Support, Aged 4 Months of Corrected Gestational Age or Older,... | bad-data | |
Trial is outside EEC | 2022-003621-21 | A Phase 3, Open-label, Non-controlled, Extension Study to Evaluate the Long-term Safety of TAK-771 in Japanese Patients with Primary Immunodeficiency Disease (PID) | bad-data | |
Trial is outside EEC, and reported results | 2022-003622-45 | A Phase 3, Open-label, Non-controlled Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Efficacy of TAK-771 in Japanese Subjects with Primary Immunodeficiency Diseases (PID) | bad-data | |
Trial is outside EEC | 2022-003877-48 | An Open-Label, Single-Dose, Phase 1/2 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Human Protein C (TAK-662) for the Treatment of Congenital Protein C Deficiency in Japanese Sub... | bad-data | |
Trial is outside EEC, and reported results | 2022-004149-11 | Phase 4, Multicenter, Prospective, Interventional, Post-Marketing Study in Hemophilia A Patients in India Receiving ADVATE as On-Demand or Prophylaxis Under Standard Clinical Practice | bad-data | |
Trial is outside EEC, and reported results | 2022-004246-35 | An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of REPLAGAL® in Treatment-naïve Chinese Subjects with Fabry Disease | bad-data | |
Trial is outside EEC | 2023-000027-36 | A Phase 3, Follow-Up Trial to Evaluate Long-Term Safety and Antibody Persistence, and the Impact of a Booster Dose of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescents and Adults in Areas ... | bad-data | |
Trial is outside EEC | 2023-000134-15 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Safety and Immunogenicity of a Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) Administered Subcutaneously to Healt... | bad-data | |
Trial is outside EEC, and reported results | 2023-001105-31 | A Multi-center, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Lanadelumab (SHP643) in Chinese Subjects with Hereditary Angioedema | bad-data |